EP1961814A4 - Rekombinanter polyvalenter impfstoff - Google Patents

Rekombinanter polyvalenter impfstoff

Info

Publication number
EP1961814A4
EP1961814A4 EP05809552A EP05809552A EP1961814A4 EP 1961814 A4 EP1961814 A4 EP 1961814A4 EP 05809552 A EP05809552 A EP 05809552A EP 05809552 A EP05809552 A EP 05809552A EP 1961814 A4 EP1961814 A4 EP 1961814A4
Authority
EP
European Patent Office
Prior art keywords
polyvalent vaccine
recombinant
recombinant polyvalent
vaccine
polyvalent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05809552A
Other languages
English (en)
French (fr)
Other versions
EP1961814A1 (de
Inventor
Yasuko Mori
Pranee Somboonthum
Hironori Yoshii
Yasuyuki Gomi
Michiaki Takahashi
Koichi Yamanishi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation for Microbial Diseases of Osaka University BIKEN
National Institute of Biomedical Innovation NIBIO
Original Assignee
Research Foundation for Microbial Diseases of Osaka University BIKEN
National Institute of Biomedical Innovation NIBIO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation for Microbial Diseases of Osaka University BIKEN, National Institute of Biomedical Innovation NIBIO filed Critical Research Foundation for Microbial Diseases of Osaka University BIKEN
Priority to EP12161513.2A priority Critical patent/EP2471937A3/de
Priority to EP12161495.2A priority patent/EP2471936A3/de
Priority to EP12161534.8A priority patent/EP2471938A3/de
Publication of EP1961814A1 publication Critical patent/EP1961814A1/de
Publication of EP1961814A4 publication Critical patent/EP1961814A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/245Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25Varicella-zoster virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/155Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165Mumps or measles virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16711Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16711Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16741Use of virus, viral particle or viral elements as a vector
    • C12N2710/16743Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16711Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16761Methods of inactivation or attenuation
    • C12N2710/16762Methods of inactivation or attenuation by genetic engineering
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18711Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18734Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/20Pseudochromosomes, minichrosomosomes
    • C12N2800/204Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/50Vectors for producing vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00Vectors comprising a special origin of replication system
    • C12N2820/55Vectors comprising a special origin of replication system from bacteria
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP05809552A 2005-11-24 2005-11-24 Rekombinanter polyvalenter impfstoff Withdrawn EP1961814A4 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP12161513.2A EP2471937A3 (de) 2005-11-24 2005-11-24 Rekombinanter polyvalenter Impfstoff
EP12161495.2A EP2471936A3 (de) 2005-11-24 2005-11-24 Rekombinanter polyvalenter Impfstoff
EP12161534.8A EP2471938A3 (de) 2005-11-24 2005-11-24 Rekombinanter polyvalenter Impfstoff

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2005/021616 WO2007060725A1 (ja) 2005-11-24 2005-11-24 組換え多価ワクチン

Publications (2)

Publication Number Publication Date
EP1961814A1 EP1961814A1 (de) 2008-08-27
EP1961814A4 true EP1961814A4 (de) 2010-01-06

Family

ID=38066967

Family Applications (4)

Application Number Title Priority Date Filing Date
EP12161513.2A Withdrawn EP2471937A3 (de) 2005-11-24 2005-11-24 Rekombinanter polyvalenter Impfstoff
EP05809552A Withdrawn EP1961814A4 (de) 2005-11-24 2005-11-24 Rekombinanter polyvalenter impfstoff
EP12161534.8A Withdrawn EP2471938A3 (de) 2005-11-24 2005-11-24 Rekombinanter polyvalenter Impfstoff
EP12161495.2A Withdrawn EP2471936A3 (de) 2005-11-24 2005-11-24 Rekombinanter polyvalenter Impfstoff

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP12161513.2A Withdrawn EP2471937A3 (de) 2005-11-24 2005-11-24 Rekombinanter polyvalenter Impfstoff

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP12161534.8A Withdrawn EP2471938A3 (de) 2005-11-24 2005-11-24 Rekombinanter polyvalenter Impfstoff
EP12161495.2A Withdrawn EP2471936A3 (de) 2005-11-24 2005-11-24 Rekombinanter polyvalenter Impfstoff

Country Status (7)

Country Link
US (1) US20100119550A1 (de)
EP (4) EP2471937A3 (de)
JP (1) JPWO2007060725A1 (de)
CN (1) CN101360823A (de)
AU (1) AU2005338519B2 (de)
CA (1) CA2630770A1 (de)
WO (1) WO2007060725A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101967466A (zh) * 2009-07-28 2011-02-09 新泽西医学院 Orf7缺陷型水痘病毒株、含有该毒株的疫苗及其应用
BR112013027247A2 (pt) * 2011-02-24 2017-08-22 Mogam Biotechnology Res Institute Cepas do vírus da varicela-zóster e vacina contra o vírus da catapora e herpes zóster usando as mesmas
CN103185794B (zh) * 2011-12-30 2015-01-07 深圳市亚辉龙生物科技有限公司 一种检测水痘-带状疱疹病毒抗体的试剂装置及其方法
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10875912B2 (en) 2016-02-05 2020-12-29 The Board Of Regents Of The University Of Texas System EGFL6 specific monoclonal antibodies and methods of their use
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN108103097B (zh) * 2017-12-04 2021-01-08 浙江大学 麻疹病毒mRNA甲基转移酶缺陷减毒疫苗株及其应用
CN111676244B (zh) * 2020-06-05 2024-02-23 成都生物制品研究所有限责任公司 以麻疹病毒为载体的麻疹、风疹联合疫苗
CN113293144B (zh) * 2021-02-01 2022-04-05 上海青赛生物科技有限公司 一种重组f基因型腮腺炎病毒活载体麻疹疫苗

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998052603A2 (en) * 1997-05-23 1998-11-26 Schweiz. Serum- & Impfinstitut Bern An influenza enveloped dna vaccine
WO2005085445A1 (ja) * 2004-03-05 2005-09-15 The Research Foundation For Microbial Diseases Of Osaka University 組換え水痘帯状疱疹ウイルス

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5341202A (en) 1976-09-28 1978-04-14 Fuji Photo Film Co Ltd Novel magnetic recording medium
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
ZA872705B (en) 1986-04-22 1987-10-05 Immunex Corporation Human g-csf protein expression
GB2206587A (en) * 1987-07-08 1989-01-11 London Biotechnology Ltd Rubella e1 glycoprotein antigens
JP3026029B2 (ja) * 1991-04-26 2000-03-27 財団法人阪大微生物病研究会 組換え水痘ウイルスとその作製法
DE69729996T2 (de) 1996-05-15 2005-08-25 The Research Foundation For Microbial Diseases Of Osaka University, Suita Methode zur identifizierung von attenuiertem varicella virus vom stamm oka oder von einem davon abstammenden stamm
US6277621B1 (en) * 1998-02-26 2001-08-21 Medigene, Inc. Artificial chromosome constructs containing foreign nucleic acid sequences
KR20010043009A (ko) 1999-02-25 2001-05-25 무타이 마사히꼬 약독수증 바이러스 오카주의 유전자 62와 이 유전자 62를이용하는 약독생수증 백신용 바이러스주의 동정방법
WO2001000234A2 (en) * 1999-06-25 2001-01-04 Maxygen, Inc. Methods and compositions for engineering of attenuated vaccines
CN100354425C (zh) * 1999-07-09 2007-12-12 美国政府健康及人类服务部 减毒的人-牛嵌合呼吸道合胞病毒疫苗的生产
AU2003206861B2 (en) * 2002-02-06 2009-04-23 Lohmann Animal Health Gmbh & Co. Kg A continuous cell line for the production of vaccines
US20080226677A1 (en) * 2004-05-06 2008-09-18 Yasuko Mori Recombinant virus vector for gene transfer into lymphoid cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998052603A2 (en) * 1997-05-23 1998-11-26 Schweiz. Serum- & Impfinstitut Bern An influenza enveloped dna vaccine
WO2005085445A1 (ja) * 2004-03-05 2005-09-15 The Research Foundation For Microbial Diseases Of Osaka University 組換え水痘帯状疱疹ウイルス
EP1721981A1 (de) * 2004-03-05 2006-11-15 The Research Foundation for Microbial Diseases of Osaka University Rekombinantes varicella-zoster-virus

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2007060725A1 *
SOMBOONTHUM ET AL: "Generation of a recombinant Oka varicella vaccine expressing mumps virus hemagglutinin-neuraminidase protein as a polyvalent live vaccine", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 25, no. 52, 5 November 2007 (2007-11-05), pages 8741 - 8755, XP022374859, ISSN: 0264-410X *

Also Published As

Publication number Publication date
EP2471937A2 (de) 2012-07-04
EP1961814A1 (de) 2008-08-27
WO2007060725A1 (ja) 2007-05-31
EP2471936A3 (de) 2013-04-24
JPWO2007060725A1 (ja) 2009-05-07
EP2471938A3 (de) 2013-04-24
CN101360823A (zh) 2009-02-04
EP2471937A3 (de) 2013-04-24
EP2471936A2 (de) 2012-07-04
US20100119550A1 (en) 2010-05-13
EP2471938A2 (de) 2012-07-04
AU2005338519A1 (en) 2007-05-31
CA2630770A1 (en) 2007-05-31
AU2005338519B2 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
EP1917040A4 (de) Polyvalenter impfstoff
EP1909829A4 (de) Rekombinante grippeimpfstoffe
EP1874346A4 (de) Rekombinante flavivirus-vakzine
IL192084A0 (en) Vaccine
GB0504436D0 (en) Vaccine
IL195683A0 (en) Recombinant viral vaccine
GB0513421D0 (en) Vaccines
ZA200705943B (en) Survivin peptide vaccine
EP1945250A4 (de) Rekombinante subunit-vakzine gegen influenza
EP1961814A4 (de) Rekombinanter polyvalenter impfstoff
ZA200709518B (en) Vaccine composition
EP1941278A4 (de) Optimaler polyvalenter impfstoff für krebs
GB0805675D0 (en) Adjuvanted vaccine
GB0524409D0 (en) Vaccines
GB0524408D0 (en) Vaccines
GB0515135D0 (en) Vaccine
ZA200709207B (en) Vaccine
GB2443591B (en) Adjuvanted vaccine
GB0516944D0 (en) Vaccine
GB0810662D0 (en) Vaccine
ZA200709210B (en) Vaccine
GB0511203D0 (en) Vaccines
GB0526412D0 (en) Vaccine
GB0406598D0 (en) Vaccine
ZA200810625B (en) Recombinant viral vaccine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080624

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE DE FR GB IT NL

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/22 20060101ALI20080924BHEP

Ipc: A61P 37/04 20060101ALI20080924BHEP

Ipc: C12N 7/00 20060101ALI20080924BHEP

Ipc: A61K 39/25 20060101ALI20080924BHEP

Ipc: C12N 5/00 20060101ALI20080924BHEP

Ipc: C12N 15/00 20060101AFI20080924BHEP

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SOMBOONTHUM, PRANEE

Inventor name: YAMANISHI, KOICHI

Inventor name: MORI, YASUKOC/O LAB. OF VIROLOGY & VACCINOLOGY

Inventor name: YOSHII, HIRONORI

Inventor name: GOMI, YASUYUKI

Inventor name: TAKAHASHI, MICHIAKI

RBV Designated contracting states (corrected)

Designated state(s): BE DE FR GB IT NL

A4 Supplementary search report drawn up and despatched

Effective date: 20091209

17Q First examination report despatched

Effective date: 20100407

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SOMBOONTHUM, PRANEE

Inventor name: YOSHII, HIRONORI

Inventor name: MORI, YASUKO

Inventor name: YAMANISHI, KOICHI

Inventor name: TAKAHASHI, MICHIAKI

Inventor name: GOMI, YASUYUKI

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/00 20060101ALI20140306BHEP

Ipc: A61K 39/165 20060101ALI20140306BHEP

Ipc: C12N 15/86 20060101ALI20140306BHEP

Ipc: A61P 37/04 20060101ALI20140306BHEP

Ipc: A61K 39/295 20060101ALI20140306BHEP

Ipc: C12N 5/00 20060101ALI20140306BHEP

Ipc: A61K 39/25 20060101AFI20140306BHEP

Ipc: C12N 7/00 20060101ALI20140306BHEP

Ipc: A61P 31/22 20060101ALI20140306BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20140703

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20141114